Greenfield Savings Bank Sells 2,907 Shares of Pfizer Inc. (NYSE:PFE)

Greenfield Savings Bank lowered its position in Pfizer Inc. (NYSE:PFE) by 7.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 38,749 shares of the biopharmaceutical company’s stock after selling 2,907 shares during the period. Greenfield Savings Bank’s holdings in Pfizer were worth $1,121,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Olistico Wealth LLC purchased a new stake in Pfizer in the 2nd quarter worth $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter valued at about $31,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC raised its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $29.19 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company’s 50-day simple moving average is $29.17 and its two-hundred day simple moving average is $28.32. Pfizer Inc. has a one year low of $25.20 and a one year high of $33.92. The company has a market capitalization of $165.41 billion, a P/E ratio of -486.50, a P/E/G ratio of 1.23 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the firm earned $0.67 earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday, October 3rd. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Barclays upped their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, StockNews.com downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. Nine equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.